Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — J.P. Morgan Healthcare Conference 2025
21 slides from Agilent Technologies's conference presentation, Jan 14, 2025
Slide 1: Agilent Technologies
Agilent Technologies Padraig McDonnell, President & CEO J.P. Morgan Healthcare Conference January 14, 2025 1
Slide 2: Safe harbor
Safe harbor This presentation contains forward-looking statements (including, without limitation, statements on Agilent's (the "company" or "our") strategy, priorities, growth and growth opportunities, productivity, reinvestment, customer focus, evolving product mix, work environment and innovation
Slide 3: Takeaways for today
Takeaways for today Established leader in $80B markets driven by secular growth Leading market share and sustainable competitive advantage via customer focus Delivering 5-7% long-term core Re-accelerating growth through innovation and market share gains growth and double-digit EPS Driving productivi
Slide 4: Leading lab partner with unsurpassed capabilities and scale
Leading lab partner with unsurpassed capabilities and scale 285K+ 110 $6.5B 26.4% $5.29 Labs served Countries served FY24 revenue FY24 operating margin(1) FY24 earnings per share(1) Lab partner with global scale Evolving product mix Services, Instrumentation Consumables 36% and Software 64% 40% 27%
Slide 5: Serving growing markets that advance quality of life
Serving growing markets that advance quality of life $80B (1) Opportunity 4-6% growth $25B (1) Pharma & 5–7% BioPharma growth Clinical & Chemical & Environmental Food Advanced & Forensics Diagnostics Materials Academic & $14B (1) $20B (1) $8B (1) $7B (1) $6B (1) 5-7% 3-5% 2-4% 2-4% Government 3-5% g
Slide 6: Agilent's strong fundamentals
Agilent’s strong fundamentals Leading Robust Record level for Unparalleled Strong free cash portfolio customer digital orders customer flow conversion retention support #1 90%+ $1B+ 90%+ 84% In key platform Customer retention Digital orders in Industry leading FY20-24 FCF as a technologies rate FY24
Slide 7: Strategy built on customer-centric vision
Strategy built on customer-centric vision Mission Vision To deliver trusted answers and insights to Innovate and deliver seamless solutions for our advance the quality of life customers to expand frontiers of science Customer end-markets Pharma & BioPharma Clinical & Diagnostics Applied Markets Stra
Slide 8: New organizational structure supports market and customer focus
New organizational structure supports market and customer focus Life Sciences & Diagnostics Applied Markets Group Agilent CrossLab Group Group (LDG) (AMG) (ACG) Simon May Mike Zhang Angelica Riemann $2.5B $1.3B $2.7B Liquid Chromatography (LC) Gas Chromatography (GC) Analytical Consumables LC Mass S
Slide 9: Launching innovative solutions to meet customer needs
Launching innovative solutions to meet customer needs Pharma & BioPharma Clinical & Diagnostics Applied Markets Upgrading solutions to Delivering superior Enhancing sensitivity and drive higher throughput patient outcomes with speed instruments for and efficiency enhanced precision high-growth appli
Slide 10: Continuing to shift portfolio towards recurring revenues
Continuing to shift portfolio towards recurring revenues Over the past decade Recent Progress Instruments Non-Instruments ~400 bps 64% FY20-24 increase in service-contract attach rate 54% 46% $1.6B in Services (2) 36% FY20-24 Core Revenue CAGR: 10% $0.9B in Consumables (3) FY20-24 Core Revenue CAGR:
Slide 11: Ignite: Embarking on a transformational journey
Ignite: Embarking on a transformational journey Simplicity & Growth Productivity & Customer- Acceleration Scalability Centricity Better combine product offerings, Operate with customer first Increase operational productivity expand portfolio, and accelerate mindset and reduce complexity in and reduc
Slide 12: Outcomes: deliver above-market growth & margin expansion
Outcomes: deliver above-market growth & margin expansion Above Market Operating Margin EPS Growth Growth Expansion Core Revenue 5-7% annually(1)(2) 50-100+ bps/yr(1) Double Digits Our new market-centric strategy and Ignite transformation drive differentiated results. Inorganic capital deployment is
Slide 13: Capturing market opportunities drives long-term growth algorithm
Capturing market opportunities drives long-term growth algorithm +5-7% (1) Long-term Projected Segment Projected Growth Long-Term Growth Key Growth Drivers +6% $6.8-6.9B(2) High-Single Digits CAGR $6.5B Increasing connect rates New productivity solutions Enterprise Solutions $5.3B 2.7 ACG 2.0 Mid to
Slide 14: Margin expansion and reinvestment enabled by Ignite
Margin expansion and reinvestment enabled by Ignite Annual Operating Margin Improvement +50-100+ bps -50 bps +50 bps Strategic 26.4%(1) Re-investment 50-100+ bps Software Leverage on Digital Annual 23.5%(1) Revenue Growth Operating Model Op Margin and Mix Pricing Expansion Procurement FY20 FY24 Reve
Slide 15: Q1 & FY25 guidance reminder
Q1 & FY25 guidance reminder Based on forecasted currency exchange rates Q1 25 Guidance (1) Low End High End FY 25 Guidance (1) Low End High End Net Revenue ($M) $1,650 $1,680 Net Revenue ($M) $6,790 $6,870 Core Revenue Growth (2) -2.0% -0.2% Core Revenue Growth (2) +2.5% +3.5% -0.3% FX, +1.8% M&A -0
Slide 16: Takeaways for today
Takeaways for today Established leader in $80B markets driven by secular growth Leading market share and sustainable competitive advantage via customer focus Delivering 5-7% long-term core Re-accelerating growth through innovation and market share gains growth and double-digit EPS Driving productivi
Slide 17: Agilent: Trusted Answers
S-- Agilent Trusted Answers
Slide 18: Reconciliation of Non-GAAP Income from Operations and Operating Margins
AGILENT TECHNOLOGIES, INC. RECONCILIATION OF NON-GAAP INCOME FROM OPERATIONS AND OPERATING MARGINS (In millions, except margin data) (Unaudited) Year Over Year Operating Operating Margin FY24 FY20 Percent Pts Margin % % Inc/(Dec) GAAP Revenue $ 6,510 $ 5,339 Income from operations: GAAP Income from
Slide 19: Reconciliation of Operating Income and Margin to Non-GAAP and Segment
AGILENT TECHNOLOGIES, INC. RECONCILIATION OF OPERATING INCOME AND MARGIN TO NON-GAAP AND SEGMENT OPERATING INCOME AND MARGIN (In millions, except margin data) (Unaudited) Operating FY24 Margin % Revenue: Life Sciences and Diagnostics Markets Group (LDG) $ 2,466 Agilent Crosslab Group (ACG) 2,747 App
Slide 20: Non-GAAP Net Income and Diluted EPS Reconciliations
AGILENT TECHNOLOGIES, INC. NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS (In millions, except per share data) (Unaudited) FY24 Net income Diluted EPS GAAP net income $ 1,289 $ 4.43 Non-GAAP adjustments: Restructuring and other related costs 76 0.26 Asset impairments 19 0.06 Intangible amortiza
Slide 21: Reconciliation of Free Cash Flows to Non-GAAP Net Income Ratio
AGILENT TECHNOLOGIES, INC. RECONCILIATION OF FREE CASH FLOWS TO NON-GAAP NET INCOME RATIO (in millions, except ratio data) (Unaudited) FY24 FY23 FY22 FY21 FY20 Total Net cash provided by operating activities $ 1,751 $ 1,772 $ 1,312 $ 1,485 $ 921 $ 7,241 Less: Payments to acquire property, plant and
Agilent Technologies — J.P. Morgan Healthcare Conference 2025 on 6ix